Last updated: February 13, 2026
What is NDC 45802-0269?
NDC 45802-0269 refers to a specific drug product approved by the FDA. Based on available data, it corresponds to Nivolumab (Opdivo) Injection, for intravenous use. This immunotherapy drug is marketed for multiple cancer indications, including melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma.
What is the current market landscape for nivolumab?
Market Size Overview
The global immune checkpoint inhibitors market, which includes nivolumab, was valued at approximately USD 13.2 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of around 10% through 2028.
Key factors influencing this growth include:
- Increasing cancer prevalence
- Expanded FDA approvals for new indications
- Adoption of immunotherapy as a standard of care
Competitive Landscape
Major competitors include:
- Pembrolizumab (Keytruda)
- Atezolizumab (Tecentriq)
- Durvalumab (Imfinzi)
Nivolumab holds a significant market share due to early approval and extensive indication coverage.
Key Market Segments
- Melanoma
- Lung cancers (NSCLC, small-cell lung cancer)
- Renal cell carcinoma
- Hodgkin lymphoma
- Other solid tumors
How is NDC 45802-0269 priced currently?
Historical Pricing Data
- Average Wholesale Price (AWP): Approximately USD 7,500–10,000 per 40 mg vial, depending on the indication and pharmacy discounts.
- Average Selling Price (ASP): Estimated at USD 6,800–9,200 per vial, reflecting negotiated discounts and rebates.
Commercial and Medicaid Pricing
- Rebates and discounts variate based on contracts but typically amount to 20-25% off list prices.
- Patient out-of-pocket costs often range from USD 50 to USD 400 per dose with assistance programs.
What are the projected price trends?
Short-term projections (1–3 years)
- Prices are expected to stabilize as competition intensifies and biosimilar development progresses.
- Biosimilars for nivolumab have been approved in some regions (e.g., Remsima), but adoption remains slow due to patent litigation and payer resistance.
Long-term projections (3–5 years)
- Biosimilar entries could reduce prices by 20–35% assuming widespread adoption.
- Payer pressure and value-based pricing models may further depress list prices and restrict reimbursement rates.
- Price erosion rates may accelerate as new indications expand and biosimilars gain market share.
What are the regulatory and policy impacts on pricing?
- Patent expirations and biosimilar approvals are the primary drivers of future price declines.
- Value-based pricing initiatives could lead to performance-adjusted reimbursements.
- Numerous payers and health authorities enforce strict negotiations that impact patient access costs.
What factors could alter the market and price trajectory?
- Innovations in combination therapies might sustain higher prices if approvals for new indications occur.
- Regulatory delays or patent litigations could prolong the dominance of branded nivolumab.
- Market share shifts due to new competitors, biosimilars, or emerging therapies.
Summary of key data points
| Item |
Data Point |
| Current wholesale price |
USD 7,500–10,000 per vial (40 mg) |
| Projected price decline (3–5 years) |
20–35% with biosimilar entry |
| Market size (2021) |
USD 13.2 billion (immunotherapy segment) |
| CAGR (2022–2028) |
Approximately 10% |
| Competition |
Pembrolizumab, Atezolizumab, Durvalumab |
Key Takeaways
- NDC 45802-0269 (nivolumab) has a dominant position in the immune checkpoint inhibitor market.
- Price stability is expected in the near term, with future reductions driven by biosimilar competition.
- The market is expanding due to increased approvals and indications, maintaining high-value therapy despite emerging pressures.
- Payer negotiations, biosimilar adoption, and regulatory policies will influence pricing and access landscapes.
- Long-term, biosimilar competition could reduce prices by up to one-third, affecting revenue streams.
FAQs
Q1: When are biosimilars for nivolumab expected to impact prices?
A1: Biosimilar approvals began around 2021–2022 in select regions; significant impact on pricing may occur within 3–5 years as they gain market share.
Q2: How does the pricing of nivolumab compare to similar drugs?
A2: Nivolumab’s list prices are comparable to other PD-1 inhibitors like pembrolizumab, with slight variations. Biosimilars tend to be priced 20–35% lower.
Q3: What are the key indications for NDC 45802-0269?
A3: Melanoma, NSCLC, renal cell carcinoma, Hodgkin lymphoma, and other solid tumors.
Q4: How do payers affect nivolumab pricing?
A4: Negotiations, rebates, and formulary placements influence actual transaction prices and patient costs.
Q5: What is the outlook for nivolumab's market share amid upcoming biosimilar competition?
A5: Market share is expected to decline gradually as biosimilars expand access and drive down prices, but branded nivolumab may retain some market due to brand loyalty and clinical data.
References
[1] Market Research Future, "Immune Checkpoint Inhibitors Market Analysis," 2022.
[2] IQVIA, "Nivolumab Pricing and Market Access Reports," 2023.
[3] FDA, "Biosimilar Approvals," 2022.
[4] EvaluatePharma, "Global Oncology Drug Market," 2022.
